A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational

A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue is a phase 2, interventional study registered as NCT07248020 by Chang Gung Memorial Hospital, with a registry enrolment figure of 72 participants, started 2026-01-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: Curcumin (BCM-95®). Conditions listed: Rectal Cancer; Locally Advanced Rectal Cancer; Radiation-Induced Enteritis; Radiation Proctitis; Chemoradiotherapy-Related Toxicity. Primary outcome: Incidence of Grade ≥3 Gastrointestinal Toxicity (Enteritis or Proctitis) During Neoadjuvant Chemoradiotherapy. Colorectal eligibility wording from the registry: "(A) Males and females more than 20 years of age (B) Signed informed consent (C) Patients with a pathologically proven rectal adenocarcinoma located less than 10 cm to the anus". Sites: Taiwan. No results are recorded here; the registry entry is the source.